<DOC>
	<DOCNO>NCT03070301</DOCNO>
	<brief_summary>The purpose study test good bad effect combination LEE011 everolimus participant cancer .</brief_summary>
	<brief_title>A Study LEE011 With Everolimus Patients With Advanced Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patient sign Informed Consent prior screen procedure perform able comply protocol requirement . Adults ≥ 18 year old Histologic cytologic diagnosis WDNET , low intermediate grade , unresectable , foregut origin ( thymic , bronchopulmonary , gastric , duodenal , pancreatic ) confirm enrol institution NOTE : Patients tumor Ki67 20 % 30 % eligible pathologist determines tumor appearance well differentiated neuroendocrine tumor . Note : If patient functional NET , permit continue somatostatin analog hormonal symptom control Patient tissue available previous biopsy evaluation potential predictive biomarkers . If tissue available , new tumor specimen need obtain prior start study treatment . Documented radiological evidence disease progression ( measurable nonmeasurable ) ≤12 month prior enrollment Disease currently amenable surgical resection curative intent determine treat investigator Measurable disease define RECIST v1.1 ECOG performance status 0 1 KPS performance status 100 70 Patient adequate bone marrow organ function define follow laboratory value screen : Absolute neutrophil count ≥1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Hemoglobin ≥ 9.0 g/dL INR ≤ 1.5 Serum creatinine &lt; 1.5mg/dL creatinine clearance ≥ 50 mL/min In absence liver metastasis , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN . If patient liver metastasis , ALT AST &lt; 5 x ULN Total bilirubin &lt; ULN ; total bilirubin ≤3.0 x ULN direct bilirubin ≤1.5 x ULN patient welldocumented Gilbert‟s Syndrome Negative serum pregnancy test do ≤14 day prior registration , woman childbearing potential A serum pregnancy test conduct &lt; 72 hour prior treatment start pretreatment parameter . All woman reproductive potential , sexually active male patient , partner patient must agree use adequate method birth control ( e.g . latex condom ) throughout study 30 day last dose study drug . † A female reproductive potential sexually mature female : undergone hysterectomy bilateral oophorectomy ; naturally postmenopausal least 24 consecutive month ( i.e . menses time precede 24 consecutive month ) . Patient standard 12lead ECG follow parameter screen ( define mean triplicate ECGs ) °QTcF interval screen &lt; 450msec ( use Fridericia‟s correction ) Must able swallow LEE011 everolimus capsules/tablets Recovered adverse event ( grade 1 less toxicity accord CTCAE 4.0 ) due agent administer previously *NOTE : Chemotherapyinduced alopecia grade 2 neuropathy acceptable Patient know hypersensitivity excipients LEE011 everolimus Previous treatment CDK 4/6 inhibitor mTOR inhibitor Has prior chemotherapy , target small molecule therapy within 2 week prior study Day 1 recover ( i.e . ≤ Grade 1 baseline ) adverse event due previously administer agent *Note : Subjects &lt; Grade 2 neuropathy chemotherapyinduced alopecia exception criterion may qualify study Patient concurrent malignancy malignancy within 3 year prior start study drug , exception adequately treat , basal squamous cell carcinoma , nonmelanomatous skin cancer curatively resect cervical cancer Patients central nervous system ( CNS ) involvement unless meet ALL follow criterion : At least 4 week prior therapy completion ( include radiation and/or surgery ) start study treatment Clinically stable CNS tumor time screen receive steroid and/or enzymeinducing antiepileptic medication brain metastasis Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) Patient know history HIV infection ( test mandatory ) Patient concurrent severe and/or uncontrolled medical condition would , investigator‟s judgment , cause unacceptable safety risk , contraindicate patient participation clinical study compromise compliance protocol ( e.g . chronic pancreatitis , active untreated uncontrolled fungal , bacterial viral infection , etc. ) . Uncontrolled diabetes mellitus define HbA1c &gt; 8 % despite adequate therapy . Patients known history impair fast glucose diabetes mellitus ( DM ) may include , however blood glucose antidiabetic treatment must monitor closely throughout trial adjust necessary Clinically significant , uncontrolled heart disease and/or cardiac repolarization abnormality , include follow : History myocardial infarction ( MI ) , angina pectoris , symptomatic pericarditis , coronary artery bypass graft ( CABG ) within 6 month prior study entry Documented cardiomyopathy Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % determined Multiple Gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) Long QT syndrome family history idiopathic sudden death congenital long QT syndrome , follow : Risk factor Torsades de Pointe ( TdP ) include uncorrected hypokalemia hypomagnesemia , history cardiac failure , history clinically significant/symptomatic bradycardia Concomitant medication ( ) know risk prolong QT interval and/or know cause Torsades de Pointe discontinue replace safe alternative medication ( e.g . within 5 halflives 7 day prior start study drug ) Inability determine QTcF interval Clinically significant cardiac arrhythmia ( e.g. , ventricular tachycardia ) , complete leave bundle branch block , highgrade AV block ( e.g. , bifascicular block , Mobitz type II third degree AV block ) Patient currently receive follow medication discontinue 7 day prior start study drug Known strong inducer inhibitor CYP3A4/5 , include grapefruit , grapefruit hybrid , pummelo , starfruit , Seville oranges , narrow therapeutic window predominantly metabolize CYP3A4/5 Herbal preparations/medications , dietary supplement Patient currently receive receive systemic corticosteroid ≤2 week prior start study drug , fully recover side effect treatment °The follow us corticosteroid permit : single dos , topical application ( e.g. , rash ) , inhale spray ( e.g. , obstructive airway disease ) , eye drop local injection ( e.g. , intraarticular ) Participation prior investigational study within 30 day prior enrollment within 5 halflives investigational product , whichever longer Patient receive radiotherapy ≤4 week limit field radiation palliation ≤2 week prior start study drug , recover grade 1 well related side effect therapy ( exception include alopecia ) ≥25 % bone marrow ( Ellis , 1961 ) irradiate Patient major surgery within 14 day prior start study drug recover major side effect ( tumor biopsy consider major surgery ) Patient ChildPugh score B C Patient history noncompliance medical regimen inability grant consent Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>LEE011</keyword>
	<keyword>Everolimus</keyword>
	<keyword>16-1535</keyword>
</DOC>